A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Abstract

Peripheral T-cell lymphoma (PTCL) is a type of highly heterogeneous non-Hodgkin lymphoma with a poor prognosis and lack of effective targeted therapies. Adoptive T-cell therapy has been successfully used in the treatment of B-cell malignancies. We first used adoptive transfer of haploidentical T cells activated by patient-specific neoantigens in vitro to treat an elderly patient with refractory angioimmunoblastic T-cell lymphoma (AITL) in 2017, and the patient achieved long-term complete remission (CR). Here we report on early results from this first-in-human phase 1 clinical trial that aims to assess the safety and tolerability of neoantigen-activated haploidentical T cell therapy (NAHTC) for relapsed/refractory PTCL.

Clinical trial registration:

http://www.chictr.org.cn/index.aspx, identifier [ChiCTR1800017440].

• Authors: Yuan Chen, Hu Zhao, Jing Luo, Youping Liao, Xu Dan, Guoyu Hu, Weiyue Gu
• Journal: Frontiers in oncology (Front Oncol) Vol. 12 Pg. 944511 ( 2022) ISSN: 2234-943X [Print] Switzerland
• PMID: 36439517 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Chen, Zhao, Luo, Liao, Dan, Hu and Gu.